Kodiak Sciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 111
- Market Cap
- $138.9M
- Introduction
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
Phase 1
Terminated
- Conditions
- Diabetic Macular EdemaWet Age-related Macular DegenerationRetinal Vein Occlusion
- Interventions
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 121
- Registration Number
- NCT03790852
- Locations
- 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Northern California Retina Vitreous Associates, Mountain View, California, United States